Blog
Medicaid GLP-1 Coverage in 2026: Which States Pay for Weight Loss Medication
Quick Answer
Only 13 state Medicaid programs pay for GLP-1 medications like Wegovy and Zepbound when prescribed for weight loss in 2026. Four states cut this benefit on January 1, 2026. Every state still covers GLP-1s for type 2 diabetes, and federal rules require coverage for heart disease, sleep apnea, and MASH indications. If your state says no, cash-pay compounded programs offer a flat-rate path that skips prior authorization entirely.
Medicaid GLP-1 coverage is one of the most confusing topics in weight loss medicine right now, and it changed dramatically in 2026. According to KFF, just 13 state Medicaid programs cover GLP-1s for obesity treatment as of January 2026, down from 16 the previous fall. Roughly 8 in 10 adult Medicaid enrollees now live in a state with no obesity GLP-1 pathway at all.
This guide gives you the full 50-state picture in one table, explains the January 2026 cuts, and shows the coverage pathways most articles miss. It also covers what to do when your state says no, because a denial for weight loss is not always the end of the road.
Medicaid GLP-1 Coverage in 2026, By the Numbers
- 13 state Medicaid programs cover GLP-1s for obesity, down from 16 in October 2025 (KFF)
- About 7.8 million of 39.5 million adult enrollees, under 20 percent, live in a covered state
- Medicaid GLP-1 prescriptions grew from about 1 million in 2019 to over 8 million in 2024
- Gross Medicaid GLP-1 spending reached nearly 9 billion dollars in 2024, before rebates of roughly 40 percent
- Nearly 40 percent of adults on Medicaid have obesity, which is why the cost math keeps breaking
- 9 states changed their coverage status in the past 12 months, affecting about 35 percent of enrollees
How Medicaid GLP-1 Coverage Works in 2026
Federal Medicaid law requires states to cover nearly all FDA-approved drugs. Weight loss medications are the big exception. States can choose to exclude drugs prescribed for weight loss, and most do. That single carve-out explains the entire patchwork below.
The same molecule can be covered or denied depending on the diagnosis on the prescription. Ozempic and Mounjaro are diabetes drugs, so every state covers them for type 2 diabetes. Wegovy and Zepbound carry weight loss indications, so states get to decide. When states do cover them for obesity, prior authorization is almost always required, with BMI thresholds and documentation of past weight loss attempts.
One more thing worth knowing before you read the table: Medicaid does not cover compounded semaglutide or compounded tirzepatide for weight loss. Compounded programs are cash-pay only, which is exactly why they have become the fallback when state coverage disappears.
Medicaid GLP-1 Coverage by State: The 2026 Table
The table below reflects the weight loss indication only, based on KFF’s January 2026 analysis and state Medicaid bulletins. Diabetes coverage exists in every state regardless of what this table says. Coverage changes quarterly, so always confirm with your state program before making decisions.
| State | 2026 Status (weight loss indication) | Notes |
| Alabama | Not covered for weight loss | Diabetes GLP-1s covered |
| Alaska | Not covered for weight loss | Diabetes GLP-1s covered |
| Arizona | Not covered for weight loss | Verify managed care plans with AHCCCS |
| Arkansas | Not covered for weight loss | Coverage bill failed to advance |
| California | Cut Jan 1, 2026 | Removed Wegovy, Zepbound, Saxenda for weight loss for adults 21 and over. Still covered for diabetes, heart disease, sleep apnea, and MASH with PA |
| Colorado | Not covered for weight loss | Diabetes GLP-1s covered |
| Connecticut | Non-GLP-1 weight loss drug only | Has proposed ending its remaining weight loss drug coverage |
| Delaware | Covered for obesity (PA required) | Wegovy, Zepbound, Saxenda with prior authorization |
| Florida | Not covered for weight loss | Reported as considering expansion in the KFF survey |
| Georgia | Not covered for weight loss | Reported as considering expansion in the KFF survey |
| Hawaii | Not covered for weight loss | Diabetes GLP-1s covered |
| Idaho | Not covered for weight loss | Diabetes GLP-1s covered |
| Illinois | Not covered for weight loss | State employee plan covers weight loss GLP-1s; Medicaid does not |
| Indiana | Not covered for weight loss | Diabetes GLP-1s covered |
| Iowa | Not covered for weight loss | Diabetes GLP-1s covered |
| Kansas | Restricted coverage (PA required) | Severe obesity pathway plus a separate Wegovy heart disease pathway |
| Kentucky | Not covered for weight loss | Diabetes GLP-1s covered |
| Louisiana | Non-GLP-1 weight loss drug only | Covers orlistat only |
| Maine | Not covered for weight loss | Diabetes GLP-1s covered |
| Maryland | Not covered for weight loss | Coverage legislation introduced but not advanced |
| Massachusetts | Restricted coverage (PA required) | Zepbound preferred for adults with BMI 30+, or 27+ with a comorbidity. MassHealth announced a shift away from ongoing weight loss GLP-1 coverage effective July 1, 2026. Verify current status |
| Michigan | Restricted coverage (PA required) | Narrowed to morbid obesity only as of Jan 1, 2026, after other interventions have failed |
| Minnesota | Covered for obesity (PA required) | Wegovy, Zepbound, Saxenda with prior authorization |
| Mississippi | Covered for obesity (PA required) | Existing coverage continues; an expansion bill was vetoed on cost grounds |
| Missouri | Covered for obesity (PA required) | Confirm covered drug list with the state PDL |
| Montana | Not covered for weight loss | Coverage bill did not advance |
| Nebraska | Not covered for weight loss | Diabetes GLP-1s covered |
| Nevada | Not covered for weight loss | Diabetes GLP-1s covered |
| New Hampshire | Cut Jan 1, 2026 | Ended weight-loss-only coverage. Other indications still covered |
| New Jersey | Not covered for weight loss | Diabetes GLP-1s covered |
| New Mexico | Non-GLP-1 weight loss drug only | May cover a non-GLP-1 weight loss drug; verify with the state |
| New York | Not covered for weight loss | Some sources list partial coverage; verify against the current state PDL |
| North Carolina | Covered for obesity (PA required) | Cut in Oct 2025 during a budget stalemate, reinstated Dec 12, 2025 |
| North Dakota | Not covered for weight loss | The 2025 state insurance mandate applies to private plans, not Medicaid |
| Ohio | Not covered for weight loss | Reported as considering expansion in the KFF survey |
| Oklahoma | Not covered for weight loss | Diabetes GLP-1s covered |
| Oregon | Not covered for weight loss | Diabetes GLP-1s covered |
| Pennsylvania | Cut Jan 1, 2026 | Ended coverage for adults 21 and over. Under-21 access preserved through EPSDT. GLP-1s had reached 22 percent of state Medicaid drug spending |
| Rhode Island | Covered for obesity (PA required) | Covered with PA; the state has been weighing new restrictions |
| South Carolina | Cut Jan 1, 2026 | Removed Wegovy and Saxenda for obesity |
| South Dakota | Not covered for weight loss | Diabetes GLP-1s covered |
| Tennessee | Covered for obesity (PA required) | Added coverage Aug 2025; Wegovy and Zepbound for members 21+ with PA |
| Texas | Non-GLP-1 weight loss drug only | May have partial non-GLP-1 coverage; reported as considering expansion |
| Utah | Covered for obesity (PA required) | Confirm covered drug list with the state PDL |
| Vermont | Non-GLP-1 weight loss drug only | Wegovy for cardiovascular risk only, not obesity alone |
| Virginia | Covered for obesity (PA required) | Requires documented medical necessity and prior authorization |
| Washington | Non-GLP-1 weight loss drug only | Apple Health ended Wegovy weight loss coverage effective Feb 1, 2026. Still covered for heart disease risk and MASH |
| West Virginia | Not covered for weight loss | State employee pilot paused over cost |
| Wisconsin | Covered for obesity (PA required) | Covered with PA; the state has been weighing new restrictions |
| Wyoming | Not covered for weight loss | Diabetes GLP-1s covered |
| Washington, D.C. | Not covered for weight loss | Verify with the District’s Medicaid program |
Reading the table: 10 states cover GLP-1s for obesity with standard prior authorization, 3 more cover them with heavy restrictions, and several cover only a non-GLP-1 weight loss drug such as orlistat, phentermine, Qsymia, or Contrave. The rest cover GLP-1s for diabetes and other qualifying conditions only.
Which States Cut Medicaid GLP-1 Coverage in 2026
The story of 2026 so far is retreat. State budgets could not absorb the cost curve. KFF reports Medicaid GLP-1 prescriptions grew from about 1 million in 2019 to over 8 million in 2024, with gross spending near 9 billion dollars. Pennsylvania alone watched GLP-1s grow from 5 percent of its Medicaid drug spending to 22 percent in three years.
The changes that matter most:
- California, New Hampshire, Pennsylvania, and South Carolina all eliminated weight loss GLP-1 coverage for adults effective January 1, 2026. California projected savings above 200 million dollars after its spending on these drugs quadrupled in 18 months. Pennsylvania projected 836 million dollars in savings.
- North Carolina cut coverage in October 2025 during a budget stalemate, then reinstated it in December 2025.
- Michigan narrowed coverage to morbid obesity only, and only after other interventions have failed.
- Massachusetts tightened criteria in early 2026 and announced a shift away from ongoing weight loss GLP-1 coverage effective July 1, 2026.
- Washington’s Apple Health ended Wegovy coverage for weight loss on February 1, 2026.
- Rhode Island, Wisconsin, and Connecticut have all been weighing further restrictions.
If you live in a state that cut coverage, note what survived. Pennsylvania preserved access for enrollees under 21 through federal EPSDT protections. California confirmed that Wegovy prescribed for MASH liver disease remains covered. The weight loss indication was cut. The other doors stayed open.
When Medicaid Must Cover a GLP-1 Regardless of State
Here is the part most coverage articles bury. The weight loss exclusion only applies to the weight loss indication. These medications now carry several FDA-approved indications that fall outside it, and coverage for those is mandatory, not optional.
| Diagnosis | Medication | Medicaid coverage |
| Type 2 diabetes | Ozempic, Mounjaro | Required in all 50 states for the diabetes indication |
| Established heart disease with BMI 27+ | Wegovy | Required. FDA approved for cardiovascular risk reduction in March 2024 |
| Moderate to severe sleep apnea with obesity | Zepbound | Required. FDA approved for OSA in December 2024 |
| MASH liver disease with fibrosis | Wegovy | Required. FDA approved in August 2025. California confirmed this pathway survives its obesity cut |
| Under age 21, medically necessary | Any GLP-1 | Protected by federal EPSDT rules even where adult coverage is excluded |
| Obesity or weight loss alone | Wegovy, Zepbound, Saxenda | Optional by state. Covered in 13 states in 2026 |
This is not a loophole. It is how the law works. If you have type 2 diabetes, documented heart disease, diagnosed sleep apnea, or MASH, your doctor may have a legitimate covered pathway even in a state that excludes weight loss drugs. The diagnosis determines the rules, and your doctor determines the diagnosis.
Two Federal Programs Could Change the Map
Some background first. In April 2025, CMS rejected a proposal that would have required Medicare and Medicaid to cover weight loss drugs nationally. Instead, two voluntary federal programs arrived in 2026, and both matter to this table.
A federal program launched May 1, 2026 may redraw this table. The CMS BALANCE Model lets state Medicaid agencies buy GLP-1s at federally negotiated prices, with applications open through July 31, 2026 and coverage going live by January 2027. States that join must adopt standardized coverage criteria and give enrollees a manufacturer-funded lifestyle program at no cost.
The honest read on BALANCE: participation is voluntary, and states under budget pressure may still decline even at lower prices. No participating states had been announced as of this writing.
The second program is the Medicare GLP-1 Bridge, launching July 2026. It gives Medicare Part D enrollees access to certain weight loss GLP-1s at a 50 dollar monthly copay, the first time Medicare has offered a weight loss pathway since the law excluded these drugs. It does not change Medicaid rules directly, but it lowers costs for dual-eligible enrollees and signals where federal policy is heading. If your state joins BALANCE or you qualify for the Bridge program, this page will reflect it, so check back.
What To Do If Your State Medicaid Says No
One structural fact first: about 78 percent of Medicaid enrollees are in managed care plans, not fee-for-service. The table above shows the state FFS baseline, but your managed care plan sets its own formulary and can differ in both directions. The state answer is your starting point, never your final answer.
A denial is a decision point, not a dead end. Work through it in this order. First, get the denial reason in writing, because a plan exclusion, a formulary issue, and a failed prior authorization each have different fixes. Second, ask your doctor whether a covered indication applies to you using the table above. Third, check your managed care plan directly, since MCO formularies can differ from the state baseline. Fourth, appeal within the window on your denial letter, and always cite EPSDT if the patient is under 21.
If every coverage door is genuinely closed, the cash-pay math is the next comparison. Brand-name GLP-1s run over 1,000 dollars per month at retail. Discount programs like GoodRx bring brand semaglutide to about 199 dollars for introductory fills, then 299 to 349 dollars per month ongoing. Compounded GLP-1 programs sit well below both. At Alternate Health Club, compounded semaglutide is 129 dollars per month and compounded tirzepatide is 169 dollars per month, flat at every dose, with no membership fees and no prior authorization process at all. You can read the full breakdown in our GLP-1 medication cost in 2026 guide and our affordable tirzepatide pricing comparison.
Two more resources worth knowing. If you have a health savings account, our HSA and FSA guide for compounded semaglutide and tirzepatide explains how pre-tax dollars can lower the real cost further. And if you are wondering whether compounded options are still available this year, our compounded semaglutide availability in 2026 article covers the current rules.
Frequently Asked Questions
Does Medicaid cover Wegovy for weight loss?
Only in the 13 states with active Medicaid GLP-1 coverage for obesity in 2026. Everywhere else, states can exclude it for weight loss. Wegovy is still covered nationwide when prescribed for cardiovascular risk reduction or MASH, because those indications sit outside the weight loss exclusion.
Which states cover GLP-1s for weight loss in 2026?
Delaware, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin cover them with prior authorization. Kansas, Massachusetts, and Michigan cover them with tighter restrictions. See the full table above for every state’s status and notes.
Did California stop covering GLP-1s for weight loss?
Yes. Medi-Cal removed Wegovy, Zepbound, and Saxenda for the weight loss indication for adults effective January 1, 2026. Coverage continues for diabetes, heart disease, sleep apnea, and MASH with prior authorization.
Does Medicaid cover Ozempic for weight loss?
Ozempic is approved for type 2 diabetes, not weight loss, so every state covers it for diabetes. Medicaid is unlikely to pay for off-label weight loss use. If you have type 2 diabetes, the diabetes indication is your covered pathway.
Does Medicaid cover Zepbound for sleep apnea?
Yes. Zepbound gained FDA approval for moderate to severe obstructive sleep apnea in adults with obesity in December 2024. That indication falls outside the weight loss exclusion, so Medicaid GLP-1 coverage applies in every state, usually with a sleep study and prior authorization.
Can my child get a GLP-1 through Medicaid?
Federal EPSDT rules require Medicaid to cover medically necessary treatment for enrollees under 21, even in states that exclude weight loss drugs for adults. Approval is case by case, not automatic. If denied, appeal and cite EPSDT.
Why did states cut GLP-1 coverage?
Cost, not effectiveness. Prescriptions grew eightfold between 2019 and 2024 and spending approached 9 billion dollars, per KFF. States facing budget pressure concluded they could not sustain the trajectory, and four ended the benefit in January 2026.
What is the CMS BALANCE Model?
A voluntary federal program that lets state Medicaid agencies cover GLP-1s at prices negotiated by CMS. It opened to states in May 2026, with participating states required to have coverage live by January 2027. Whether it expands Medicaid GLP-1 coverage depends entirely on which states join.
Does Medicaid cover compounded semaglutide?
No. Compounded semaglutide and tirzepatide are not FDA-approved products and are not a Medicaid benefit. They are available only through cash-pay telehealth programs, which is why flat-rate pricing matters so much for people whose state coverage ended.
What is the cheapest GLP-1 option without Medicaid coverage?
Compounded programs are typically the lowest-cost path. Flat-rate options like AHC’s 129 dollar per month compounded semaglutide cost less than a tenth of brand-name retail prices, with no insurance paperwork and no dose-based price increases.
Ready to start your GLP-1 journey?
If your state Medicaid program will not cover GLP-1 therapy for weight loss, AHC’s licensed physicians build personalized protocols with transparent flat-rate pricing and no insurance hurdles, all online, no clinic visit required. Compounded semaglutide from $129/month. Compounded tirzepatide from $169/month. Begin your free evaluation today!
Medical Disclaimer:
Compounded semaglutide and tirzepatide are not FDA-approved finished drug products and have not been evaluated by the FDA for safety, efficacy, or quality. All prescriptions at Alternate Health Club are issued by independently licensed U.S. healthcare providers following individual patient evaluations. Individual results vary. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any medical treatment.